Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Status:
Terminated
Trial end date:
2019-03-09
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, open-label, 3-arm trial in the ratio of 1:1:1 to either Sym004
(Arm A) versus each of its component monoclonal antibodies (mAbs), futuximab (Arm B) or
modotuximab (Arm C), in genomically-selected patients with chemotherapy-refractory metastatic
colorectal carcinoma (mCRC) and acquired resistance to anti-epidermal growth factor receptor
(anti-EGFR) mAb therapy. The study is designed to evaluate the relative antitumor activity of
each agent as assessed by imaging studies performed after 8 weeks of treatment.